Market Research Report
Europe Proteomics Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||823177|
|Published||Content info||112 Pages
Delivery time: 2-3 business days
|Europe Proteomics Market Forecast 2019-2027|
|Published: April 15, 2019||Content info: 112 Pages||
The advancement in proteomic technologies, increase in R&D expenditure, technological advancements and the increasing use of proteomics information are essentially driving the market in the Europe regional market for proteomics. The Europe proteomics market is anticipated to generate revenue of $XX billion by 2027 and to grow at a CAGR of 14.49% between 2019 and 2027.
The European proteomics market includes Germany, France, the UK, Italy, Spain and Rest of Europe. Europe has emerged as the second largest potential market for proteomics. As proteomic technologies are applicable in a wide range of clinical studies, the European Commission co-funded a project on proteomics by investing $XX million in 2015 for four years under the Horizon 2020 Program.
Proteomics research requires huge capital investment, which is supported by public funding institutions but results in a low outcome. The proteomics market is expected to witness significant growth. Therefore, the government and federal ministries across several countries in the region have invested in the industry to drive the market growth.
Thermo Fisher Scientific Inc., Bruker Corporation, Danaher Corporation, Merck & Company Inc., GlaxoSmithKline, Agilent Technologies, Inc., LI-COR Inc., General Electric Company, Luminex Corp., PerkinElmer, Inc., Horiba, Ltd., Bio-Rad Laboratories, Inc., Waters Corporation, Caprion Biosciences (acquired by GHO Capital), and Qiagen N.V. are the major companies operating in the market.